daneng li, md, on combining cabozantinib with checkpoint inhibitors to improve patient outcomes
Published 4 years ago • 50 plays • Length 2:50
Download video MP4
Download video MP3
Similar videos
-
2:33
daneng li, md, on impressions of patient reported outcomes from the imbrave 150 study
-
3:20
daneng li, md, regarding the role of immunotherapy in the neoadjuvant and adjuvant setting for hcc
-
3:10
daneng li, md, on the study results investigating the geriatric assessment tool & chemo side effects
-
1:47
daneng li, md, considers the role of immuno-oncology in the management of hcc
-
1:37
jing liang, md
-
5:06
the potential for combining checkpoint inhibitors
-
8:17
immune checkpoint inhibitors
-
7:10
life as an emergency medicine doctor - should you choose this residency/specialty?
-
4:25
imbrave150 in unresectable hcc
-
0:36
nevena damjanov, md, on the outcomes of combining atezolizumab with bevacizumab in hcc patients
-
1:40
pros and cons of immune checkpoint inhibitors for tumor immunotherapy
-
1:00
meet prakash jayakumar
-
5:18
what patients with aml benefit from therapy with checkpoint inhibitors?
-
0:38
how immunotherapy works
-
1:37
liza m. cohen, md
-
4:20
checkpoint inhibitors show few efficacy, safety differences
-
8:02
covid 19 vaccine and immune checkpoint inhibitors
-
52:04
innate lymphoid cell/eosinophil collaboration re-shapes melanoma outcomes by dr. gabrielle belz
-
4:57
common pulmonary side effects seen in checkpoint inhibitors & immunotherapy & how are they managed?
-
5:48
how do checkpoint inhibitors and targeted therapies work together to treat kidney cancer?
-
23:02
immunotherapy: moving beyond pd1 and pdl1 inhibitors
-
4:49
common skin side effects seen with checkpoint inhibitors & immunotherapy and how are they managed?
Clip.africa.com - Privacy-policy